Overview

A Phase I Trial of HS-10241 in Solid Tumors

Status:
Completed

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

Summary

This is a phase 1, open-label, dose-escalation trial of HS-10241 as monotherapy in subjects with solid tumors. HS-10241 will be administered orally once daily.

Phase:

Phase 1

Details

Lead Sponsor:

Atridia Pty Ltd.